The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward

In this CME Outfitters Live and OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

At the end of this CE activity, participants should be able to:
-Apply molecular testing to identify predictive biomarkers for targeted therapy in advanced NSCLC.
-Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC
-Employ best practices to manage lung cancer during the COVID-19 pandemic.

The following learning objectives pertain only to those requesting CNE or CPE credit:
-Summarize how molecular testing can identify predictive biomarkers for targeted therapy in advanced NSCLC.
-Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC.
-Describe best practices to manage lung cancer during the COVID-19 pandemic.